Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

Congenital HI is a rare genetic condition that results in persistent hypoglycemia due to the overproduction of insulin. Ersodetug, a fully human monoclonal antibody, binds allosterically to insulin ...

Single inhaled treatment produced significant reductions in symptoms within 24 hours, but effects were not sustained at one week.

While the CDC report is delayed, non-government researchers are tracking trends in real time. A December 9 report from #WeCount, sponsored by the Society of Family Planning, found that abortions in ...

Pegcetacoplan yields significantly greater change in proteinuria than placebo in C3 glomerulopathy or primary immune-complex MPGN.

HealthDay News — A widely used blood pressure medication is being pulled from shelves after testing suggested some batches may contain traces of other drugs. Glenmark Pharmaceuticals has recalled ...

Findings seen for older adults experiencing gabapentinoid (gabapentin and pregabalin)-edema-loop diuretic prescribing cascade ...

Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.